Novo Nordisk a S: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Feb 5, 2025 and accepted by EDGAR at Feb 5, 2025, 07:04 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | DKK 290.40bn | ifrs-full:Revenue |
| Cost of revenue | 12 months2024-01-01 to 2024-12-31 | DKK 44.52bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2024-01-01 to 2024-12-31 | DKK 245.88bn | ifrs-full:GrossProfit |
| Operating income | 12 months2024-01-01 to 2024-12-31 | DKK 128.34bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2024-01-01 to 2024-12-31 | DKK 26.20bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2024-01-01 to 2024-12-31 | DKK 100.99bn | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | DKK 22.63 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | DKK 22.67 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | DKK 120.97bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | DKK 47.16bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2024-12-31 | DKK 15.65bn | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2024-12-31 | DKK 160.90bn | ifrs-full:CurrentAssets |
| Total assets | At period end2024-12-31 | DKK 465.80bn | ifrs-full:Assets |
| Current liabilities | At period end2024-12-31 | DKK 217.53bn | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2024-12-31 | DKK 322.31bn | ifrs-full:Liabilities |
| Shareholders' equity | At period end2024-12-31 | DKK 143.49bn | ifrs-full:Equity |
Source: SEC EDGAR, the filing index for accession 0001628280-25-003920. Last ingested by Listed: Oct 26, 2026, 12:35 ET. Listed shows no prices and gives no investment advice.